PC
VRTX icon

Paulson & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Paulson & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-61,500
Closed -$4.89M – 98
2016
Q1 		$4.89M Buy
61,500
+15,100
+33% +$1.37M 0.04% 69
2015
Q4 		$5.84M Buy
+46,400
New +$5.6M 0.03% 55

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Paulson & Co's VRTX Position: Q2 2016 in Review

Paulson & Co sold out of Vertex Pharmaceuticals (VRTX) in Q2 2016, closing a stake of 61,500 shares — an estimated $4.89M sold.

Paulson & Co first reported a position in VRTX in Q4 2015 and held it in 2 quarters. The position peaked at $5.84M in Q4 2015. 482 funds tracked by Wall St. Rank hold VRTX as of Q2 2016.

  • Paulson & Co reported no remaining Vertex Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Paulson & Co sold 61,500 Vertex Pharmaceuticals shares in Q2 2016, an estimated $4.89M.
  • Paulson & Co first reported a position in Vertex Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • Paulson & Co's Vertex Pharmaceuticals position peaked at $5.84M in Q4 2015.
  • 482 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2016.

Based on Paulson & Co's 13F filing for Q2 2016, filed 15 Aug 2016.